Results of a salvage regimen in refractory or relapsed non-hodgkin's lymphoma

Roberto Buzzoni, Marco Colleoni, Patrizia Nelli, Franco Nole, Emilio Bajetta

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

After therapy with adriamycin-containing regimens, relapsed or refractory non-Hodgkin's lymphomas (NHL) have a very poor prognosis. Although high dose chemotherapies are widely employed, their related costs and the controversial results achieved justify the development of new second-line conventional therapies. Forty-three patients with relapsed or refractory NHL were consequently treated with an outpatient polychemotherapy schedule including ifos-famide, mitoxantrone and etoposide on day 1, and vindesine, cisplatinum and cytosine ara-binoside on day 15. The courses were repeated on day 29. All of the patients were pretreated with at least one chemotherapy regimen. Twenty-two patients had diffuse large cell lymphoma, 8 had bone marrow involvement, and 17 altered baseline lactate dehydrogenase (LDH) values. After a median number of 4 cycles (range 2-8), we registered 20 complete (46% and 4 partial remissions, for an overall remission rate of 56% (95% confidence interval: 40-71% All of the responses occurred in patients who had achieved at least partial remission during first-line therapy. Four patients are long term responders after 31, 39, 49 and 52 months, and are possibly cured. Univariate analysis of prognostic factors showed that baseline LDH values and response to front-line therapy significantly affected both time to disease progression and survival, whereas the number of previous treatments given, significantly affected only the time to progression. Therapy was administered in an out-patient setting and no life-threatening toxicity was observed. Side effects consisted of nausea/vomiting, alopecia and reversible myelosuppression. The results suggest that different treatment strategies for relapsed and refractory patients should be considered on the basis of prognostic factors. The proposed schedule may be potentially curative in a subgroup of relapsed patients at better risk; poor risk refractory patients should be considered for investigational trials involving high-dose chemotherapy.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalLeukemia and Lymphoma
Volume14
Issue number1-2
DOIs
Publication statusPublished - 1994

Fingerprint

Non-Hodgkin's Lymphoma
L-Lactate Dehydrogenase
Drug Therapy
Therapeutics
Appointments and Schedules
Outpatients
Vindesine
Mitoxantrone
Lymphoma, Large B-Cell, Diffuse
Cytosine
Alopecia
Etoposide
Combination Drug Therapy
Doxorubicin
Nausea
Vomiting
Disease Progression
Bone Marrow
Confidence Intervals
Costs and Cost Analysis

Keywords

  • Non-Hodgkin's lymphoma
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Results of a salvage regimen in refractory or relapsed non-hodgkin's lymphoma. / Buzzoni, Roberto; Colleoni, Marco; Nelli, Patrizia; Nole, Franco; Bajetta, Emilio.

In: Leukemia and Lymphoma, Vol. 14, No. 1-2, 1994, p. 121-128.

Research output: Contribution to journalArticle

@article{12aef1805a794d7a8bd67fdcbdd6b491,
title = "Results of a salvage regimen in refractory or relapsed non-hodgkin's lymphoma",
abstract = "After therapy with adriamycin-containing regimens, relapsed or refractory non-Hodgkin's lymphomas (NHL) have a very poor prognosis. Although high dose chemotherapies are widely employed, their related costs and the controversial results achieved justify the development of new second-line conventional therapies. Forty-three patients with relapsed or refractory NHL were consequently treated with an outpatient polychemotherapy schedule including ifos-famide, mitoxantrone and etoposide on day 1, and vindesine, cisplatinum and cytosine ara-binoside on day 15. The courses were repeated on day 29. All of the patients were pretreated with at least one chemotherapy regimen. Twenty-two patients had diffuse large cell lymphoma, 8 had bone marrow involvement, and 17 altered baseline lactate dehydrogenase (LDH) values. After a median number of 4 cycles (range 2-8), we registered 20 complete (46{\%} and 4 partial remissions, for an overall remission rate of 56{\%} (95{\%} confidence interval: 40-71{\%} All of the responses occurred in patients who had achieved at least partial remission during first-line therapy. Four patients are long term responders after 31, 39, 49 and 52 months, and are possibly cured. Univariate analysis of prognostic factors showed that baseline LDH values and response to front-line therapy significantly affected both time to disease progression and survival, whereas the number of previous treatments given, significantly affected only the time to progression. Therapy was administered in an out-patient setting and no life-threatening toxicity was observed. Side effects consisted of nausea/vomiting, alopecia and reversible myelosuppression. The results suggest that different treatment strategies for relapsed and refractory patients should be considered on the basis of prognostic factors. The proposed schedule may be potentially curative in a subgroup of relapsed patients at better risk; poor risk refractory patients should be considered for investigational trials involving high-dose chemotherapy.",
keywords = "Non-Hodgkin's lymphoma, Salvage chemotherapy",
author = "Roberto Buzzoni and Marco Colleoni and Patrizia Nelli and Franco Nole and Emilio Bajetta",
year = "1994",
doi = "10.3109/10428199409049657",
language = "English",
volume = "14",
pages = "121--128",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "1-2",

}

TY - JOUR

T1 - Results of a salvage regimen in refractory or relapsed non-hodgkin's lymphoma

AU - Buzzoni, Roberto

AU - Colleoni, Marco

AU - Nelli, Patrizia

AU - Nole, Franco

AU - Bajetta, Emilio

PY - 1994

Y1 - 1994

N2 - After therapy with adriamycin-containing regimens, relapsed or refractory non-Hodgkin's lymphomas (NHL) have a very poor prognosis. Although high dose chemotherapies are widely employed, their related costs and the controversial results achieved justify the development of new second-line conventional therapies. Forty-three patients with relapsed or refractory NHL were consequently treated with an outpatient polychemotherapy schedule including ifos-famide, mitoxantrone and etoposide on day 1, and vindesine, cisplatinum and cytosine ara-binoside on day 15. The courses were repeated on day 29. All of the patients were pretreated with at least one chemotherapy regimen. Twenty-two patients had diffuse large cell lymphoma, 8 had bone marrow involvement, and 17 altered baseline lactate dehydrogenase (LDH) values. After a median number of 4 cycles (range 2-8), we registered 20 complete (46% and 4 partial remissions, for an overall remission rate of 56% (95% confidence interval: 40-71% All of the responses occurred in patients who had achieved at least partial remission during first-line therapy. Four patients are long term responders after 31, 39, 49 and 52 months, and are possibly cured. Univariate analysis of prognostic factors showed that baseline LDH values and response to front-line therapy significantly affected both time to disease progression and survival, whereas the number of previous treatments given, significantly affected only the time to progression. Therapy was administered in an out-patient setting and no life-threatening toxicity was observed. Side effects consisted of nausea/vomiting, alopecia and reversible myelosuppression. The results suggest that different treatment strategies for relapsed and refractory patients should be considered on the basis of prognostic factors. The proposed schedule may be potentially curative in a subgroup of relapsed patients at better risk; poor risk refractory patients should be considered for investigational trials involving high-dose chemotherapy.

AB - After therapy with adriamycin-containing regimens, relapsed or refractory non-Hodgkin's lymphomas (NHL) have a very poor prognosis. Although high dose chemotherapies are widely employed, their related costs and the controversial results achieved justify the development of new second-line conventional therapies. Forty-three patients with relapsed or refractory NHL were consequently treated with an outpatient polychemotherapy schedule including ifos-famide, mitoxantrone and etoposide on day 1, and vindesine, cisplatinum and cytosine ara-binoside on day 15. The courses were repeated on day 29. All of the patients were pretreated with at least one chemotherapy regimen. Twenty-two patients had diffuse large cell lymphoma, 8 had bone marrow involvement, and 17 altered baseline lactate dehydrogenase (LDH) values. After a median number of 4 cycles (range 2-8), we registered 20 complete (46% and 4 partial remissions, for an overall remission rate of 56% (95% confidence interval: 40-71% All of the responses occurred in patients who had achieved at least partial remission during first-line therapy. Four patients are long term responders after 31, 39, 49 and 52 months, and are possibly cured. Univariate analysis of prognostic factors showed that baseline LDH values and response to front-line therapy significantly affected both time to disease progression and survival, whereas the number of previous treatments given, significantly affected only the time to progression. Therapy was administered in an out-patient setting and no life-threatening toxicity was observed. Side effects consisted of nausea/vomiting, alopecia and reversible myelosuppression. The results suggest that different treatment strategies for relapsed and refractory patients should be considered on the basis of prognostic factors. The proposed schedule may be potentially curative in a subgroup of relapsed patients at better risk; poor risk refractory patients should be considered for investigational trials involving high-dose chemotherapy.

KW - Non-Hodgkin's lymphoma

KW - Salvage chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0028305999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028305999&partnerID=8YFLogxK

U2 - 10.3109/10428199409049657

DO - 10.3109/10428199409049657

M3 - Article

VL - 14

SP - 121

EP - 128

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -